 | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | IV |
| ATCvet code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.158.065 |
| Chemical and physical data | |
| Formula | C9H9BrFN3 |
| Molar mass | 258.094 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Romifidine is adrug that is used inveterinary medicine as asedative mainly in large animals such as horses,[1] although it may be used in a wide variety of species.[2][3] It is not used in humans, but is closely related in structure to the commonly used drugclonidine.
Romifidine acts as anagonist at the α2adrenergic receptor subtype. Side effects can includebradycardia andrespiratory depression. It is often used alongside other sedative or analgesic drugs such asketamine orbutorphanol.[4][5]Yohimbine can be used as anantidote to rapidly reverse the effects.
Romifidine is licensed for cats and dogs in several countries. Romifidine is licensed for non-meat horses. Romifidine may produce lessataxia during standing sedation than other α2-adrenergic receptor agonists.[6]
Romifidine is anα2-adrenergic receptor agonist that binds at a ratio of 340:1 over theimidazoline receptor.[6]
Romifidine administration in sheep activates pulmonarymacrophages that damage theendothelium of capillaries andalveolar type I cells. This in turns causes alveolarhaemorrhage and oedema causinghypoxaemia.[6][7][8]
